相关实验视频
Updated: Jul 15, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.7K
糖尿病及其并发症中的藻类衍生的天然产品-目前的进展和未来的前景
Leonel Pereira1,2, Ana Valado2,3
1Department of Life Sciences, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal.
Life (Basel, Switzerland)
|September 28, 2023
概括
来自藻类的天然产品在治疗糖尿病方面表现有前途. 本综述探讨了它们的潜力,机制和挑战,为开发新型抗糖尿病治疗提供了见解.
科学领域:
- 海洋生物学 海洋生物学
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
背景情况:
- 糖尿病是一种主要的全球健康问题,需要新的治疗策略.
- 自然产品,特别是来自藻类的产品,越来越多地被认为具有潜在的抗糖尿病特性.
- 藻类提供了多样化的生物活性化合物的来源,具有治疗应用.
研究的目的:
- 为糖尿病管理提供藻类衍生的天然产品的全面审查.
- 突出这一领域最近的进展和未来的方向.
- 检查利用藻类化合物在糖尿病护理中的潜力和挑战.
主要方法:
- 科学数据库的文献综述,重点关注藻类和糖尿病.
- 来自各种藻类物种的生物活性成分的分析.
- 检查潜在的抗糖尿病作用的药理机制.
主要成果:
- 藻类含有各种生物活性化合物,具有显著的抗糖尿病潜力.
- 特定的藻类衍生物在治疗糖尿病的各个方面表现出有效性.
- 确定的挑战包括提取,标准化和临床翻译.
结论:
- 来自藻类的天然产品代表了新型抗糖尿病药物发现的有希望的途径.
- 需要进一步的研究来优化基于藻类的干预措施并克服局限性.
- 继续进行调查可以改善糖尿病管理和患者的治疗结果.
相关概念视频
Diabetes: Management and Pharmacotherapy
302
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
302
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Diabetes: Symptoms, Diagnosis, and Complications
573
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
573
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196
Pathophysiology of Diabetes
971
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
971
Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348

